Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs

Clinical Biochemistry

Volumn 31, Issue 5, 1998, Pages 381-384

  Soldin, Steven J ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; CYCLOSPORIN A; DRUG METABOLITE; FK 506 BINDING PROTEIN; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

CONFERENCE PAPER; DISSOCIATION CONSTANT; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MASS SPECTROMETRY; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL;

ANIMALS; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOASSAY; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; SIROLIMUS; TACROLIMUS;

EID: 0032128071     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00046-0     Document Type: Conference Paper

References (27)

1. Schreiber S.L. Using the principles of organic chemistry to explore cell biology. Chem Eng News. 70:1992;22-32.
2. Donnelly J.G., Soldin S.J. A radioreceptor assay for the measurement of cyclosporine activity a preliminary report . Ther Drug Monit. 11:1989;696-700.
3. Russell R., Donnelly J., Palasynski E., Chan M., Soldin S.J. A preliminary study to evaluate an in vitro assay for determining patient whole blood immunosuppressive cyclosporine A and metabolite activity comparison with cytosolic binding assays using cyclophilin or a 50-kDa binding protein, and the Abbott TDx cyclosporin A parent, and parent and metabolites assays . Ther Drug Monit. 13:1991;32-36.
4. Murthy J.N., Chen Y., Warty V.S., et al. Radioreceptor assay for quantifying FK-506 in whole blood. Clin Chem. 38:1992;1307-1310.
5. Harding M.W., Galat A., Uehling D.E., Schreiber S.L. A receptor for the immunosuppressant FK-506 is a cis-trans-peptidyl-propyl isomerase. Nature. 341:1989;758-760.
6. Fretz H., Albers M.W., Galat A., et al. Rapamycin and FK-506 binding proteins (immunophilins). J Am Chem Soc. 113:1991;1409-1411.
7. Murthy J.N., Chen Y., Soldin S.J. Identification of a 14 kDa FK-506/rapamycin binding immunophilin from calf thymus. Clin Biochem. 27:1994;357-365.
8. Donnelly J.G., Soldin S.J. Partial characterization of 52 kDa CsA/FK-506/rapamycin binding protein. Clin Biochem. 27:1994;367-372.
9. Donnelly J.G., Soldin S.J. Purification of a 50-58 kDa Immunophilin from human spleen and a Jurkat T-cell line which is capable of binding cyclosporin A, FK-506 and rapamycin. Transplant Proc. 23:1991;2886-2889.
10. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin a specific binding protein for cyclosporine A . Science. 226:1984;544-547.
11. Bierer B.E., Mattila P.S., Standaert R.F., et al. Two distinct signal transmission pathways in T-lymphocytes are inhibited by complexes formed between an immunophilin and either FK-506 or rapamycin. Proc Natl Acad Sci USA. 87:1990;9231-9235.
12. Bierer B.E., Jin Y.J., Fruman D.A., Calvo V., Burakoff S.J. FK-506 and rapamycin molecular probes of T-lymphocyte activation . Transplant Proc. 23:1991;2850-2855.
13. Siekierka J.J., Hung S.H., Poe M., Lin C.S., Sigal N.H. A cytosolic binding protein for the immunosuppressant FK-506 has peptidyl-prolylisomerase activity but is distinct from cyclophilin. Nature. 341:1989;755-757.
14. Soldin S.J. Receptor (Immunophilin-Binding) assay for immunosuppressive drugs. Ther Drug Monit. 17:1995;574-576.
15. Murthy J.N., Goodyear N., Soldin S.J. Identification of a 37 kDa tacrolimus, sirolimus and cyclosporine binding immunophilin possessing glyceraldehyde-3 phosphate dehydrogenase activity isolated from the Jurkat T-cell line. Clin Biochem. 30:1997;129-133.
16. Goodyear N., Murthy J.N., Soldin S.J. The 37 kDa immunophilin has uracil DNA glycosylase but not rotamase activity. Clin Biochem. 30:1997;497-499.
17. Rosano T., Freed B., Cerill J. Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients. Transplantation. 42:1986;262-267.
18. Copeland K.R., Yatscoff R.W., McKenna R.M. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectrometry and nuclear magnetic resonance. Clin Chem. 36:1990;225-229.
19. Murthy J.N., Yatscoff R.W., Soldin S.J. Cyclosporine metabolite cross-reactivity in different cyclosporine assays. Clin Biochem. 31:1998;159-163.
20. Huupponen R., Hirvisalo E., Nenvonen P. Comparison of cyclophilin binding assay and radioimmunoassay in monitoring of blood cyclosporine. Ther Drug Monit. 19:1997;446-449.
21. Jusko W.J., Thomson A.W., Fung J., et al. Consensus document therapeutic monitoring of tacrolimus (FK-506) . Ther Drug Monit. 17:1995;606-614.
22. Tamura K., Fujimura T., Iwasak K., et al. Interaction of tacrolimus (FK-506) and its metabolites with FKBP and calcineurin. Biochem Biophys Res Comm. 202:1994;437-443.
23. Murthy JN, Yatscoff RW, Soldin SJ. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin Biochem, in press.
24. Christians U., Sattler M., Schiebel H.M., et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Met Dispos. 20:1992;186-191.
25. Yatscoff R.W., Wang P., Chan K., et al. Rapamycin distribution, pharmacokinetics and therapeutic range investigations . Ther Drug Mont. 17:1995;666-671.
26. Goodyear N., Murthy J.N., Gallant H.L., Yatscoff R.W., Soldin S.J. Comparison of binding characteristics of four rapamycin metabolites to the 14 and 52 kDa immunophilins with their pharmacologic activity as measured in the mixed lymphocyte culture assay. Clin Biochem. 29:1996;309-313.
27. Goodyear N., Napoli K.L., Murthy J., Kahan B.D., Soldin S.J. The radioreceptor assay for sirolimus in patients with low platelet counts. Clin Biochem. 30:1997;539-543.